UK markets open in 4 hours 56 minutes

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.4600-0.0050 (-1.08%)
At close: 03:59PM EDT

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
https://www.nwbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees25

Key executives

NameTitlePayExercisedYear born
Ms. Linda F. Powers J.D.Chairperson, CEO, President, CFO & Chief Accounting Officer1.1MN/A1956
Dr. Alton L. Boynton Ph.D.Founder, Chief Scientific Officer, Secretary & Director450kN/A1945
Dr. Marnix L. Bosch M.B.A., Ph.D.Chief Technical Officer597.5kN/A1959
Mr. Leslie J. GoldmanSenior VP & General Counsel825kN/A1945
Ms. Jean M. DavisChief Information Officer258.78kN/A1972
Mr. David InnesVice President of Investor RelationsN/AN/AN/A
Mr. Pankaj R. Shah C.A., CPAFinancial ControllerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Corporate governance

Northwest Biotherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.